查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1581226

核酸治疗 CDMO 市场：按类型、服务、应用和最终用户 - 2025-2030 年全球预测

Nucleic Acid Therapeutics CDMO Market by Type (DNA Therapeutics, RNA Therapeutics), Service (Analytical and Quality Control Services, Manufacturing Services, Process Development and Optimization), Application, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年核酸治疗CDMO市场规模为96.9亿美元，预计2024年将达到105.8亿美元，复合年增长率为9.64%，预计到2030年将达到184.7亿美元。

作为 360iResearch 的市场研究分析师，了解这个新兴市场的范围和细微差别对于关注核酸治疗的合约研究、开发和受託製造厂商(CDMO) 领域至关重要。核酸疗法，包括 mRNA、siRNA 和反义寡核苷酸，正在重新定义标靶治疗，并为遗传性疾病、癌症和病毒感染的治疗提供了巨大潜力。这些疗法的需求和应用突显出它们直接针对遗传条件的能力，提供了传统治疗方法无法实现的精确治疗选择。最终用途主要是生物技术和製药公司，专门从事个人化医疗并扩大其开发平臺以纳入这些新颖的治疗方法。市场成长是由基因序列测定技术进步、慢性病盛行率上升以及个人化医疗趋势不断增长所推动的。此外，公共和私人投资正在加速这些突破性治疗方法的开发。然而，仍有可能阻碍市场扩张的挑战，例如高製造成本、扩充性问题、严格的法规环境和复杂的製造流程。机会在于发展伙伴关係关係，促进经济高效的製造技术、增强的交付机制和技术共用的创新，以克服当前的限制。 CDMO 可以透过投资先进的技术平台（例如整合数位解决方案和自动化）来利用需求激增的机会，从而提高扩充性、法规遵循和上市速度。技术创新的关键领域包括脂质奈米颗粒等递送系统的改进以及稳定製剂技术的发展，以确保将核酸有效负载安全地递送至目标细胞。适应市场的性质需要灵活的方法和扩大的产品组合，包括从开发到商业生产的综合服务。透过了解这些市场动态和潜在机会，公司可以更好地推进核酸疗法，解决未满足的医疗需求，并推动这一创新领域的强劲成长。

主要市场统计
基准年[2023] 96.9亿美元
预测年份 [2024] 105.8亿美元
预测年份 [2030] 184.7亿美元
复合年增长率（%） 9.64%

市场动态：快速发展的核酸治疗 CDMO 市场揭示的关键市场洞察

核酸疗法 CDMO 市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球遗传病患疾病率不断上升
    • 增加经费和投入支持核酸研究
  • 市场限制因素
    • 核酸疗法的製造成本高
  • 市场机会
    • 增加对核酸疗法的监管核准
    • 个人化医疗的扩展带来巨大潜力
  • 市场挑战
    • 核酸疗法扩充性的限制

波特五力：引领核酸治疗 CDMO 市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解核酸治疗 CDMO 市场的外部影响

外部宏观环境因素在塑造核酸治疗 CDMO 市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解核酸治疗 CDMO 市场的竞争状况

对核酸治疗 CDMO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵核酸治疗 CDMO 市场供应商的绩效评估

FPNV定位矩阵是评估核酸治疗CDMO市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划核酸治疗 CDMO 市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对核酸治疗 CDMO 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、核准核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地遗传性疾病的发生率正在增加
      • 增加资金和投资支持核酸研究
    • 抑制因素
      • 核酸疗法生产成本高
    • 机会
      • 核酸疗法的监管核准增加
      • 个人化医疗的扩展带来巨大潜力
    • 任务
      • 核酸治疗的扩充性有限
  • 市场区隔分析
    • 类型：随着感染疾病传播的增加，mRNA疗法持续取得进展
    • 应用：癌症发生率的增加增加了对创新和有效的癌症治疗的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 核酸治疗 CDMO 市场：依类型

  • DNA疗法
  • RNA疗法

第七章核酸治疗 CDMO 市场：依服务分类

  • 分析和品管服务
  • 製造服务
  • 製程开发与最佳化

第八章核酸治疗药物CDMO市场：依应用分类

  • 遗传疾病
  • 感染疾病
  • 肿瘤学

第 9 章 核酸治疗 CDMO 市场：依最终使用者分类

  • 生技公司
  • 政府及学术研究机构
  • 製药公司

第十章 北美及南美核酸治疗CDMO市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区核酸治疗CDMO市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲核酸治疗药物CDMO市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FUJIFILM Toyama Chemical 与 Synprogen 合作加强 mRNA 治疗药物的生产
    • Exothera 在北美推出先进的 RNA 治疗平台“Ntensify”，简化核酸药物开发
  • 战略分析和建议

公司名单

  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Rentschler Biopharma SE
  • Sanofi SA
  • The Scripps Research Institute
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market was valued at USD 9.69 billion in 2023, expected to reach USD 10.58 billion in 2024, and is projected to grow at a CAGR of 9.64%, to USD 18.47 billion by 2030.

As a Market Research Analyst at 360iResearch focusing on the Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) sector, it's essential to understand the scope and nuances of this evolving industry. Nucleic acid therapeutics, including mRNA, siRNA, and antisense oligonucleotides, are reshaping targeted therapies, offering immense promise in treating genetic disorders, cancers, and viral infections. The necessity and application of these therapeutics are underscored by their ability to target genetic conditions directly, providing precision treatment options that traditional therapies may not achieve. End-use is primarily in biotechnology and pharmaceutical companies dedicated to personalized medicine, expanding their R&D pipelines to include these novel modalities. Market growth is driven by technological advancements in genetic sequencing, increasing prevalence of chronic diseases, and a rising trend towards personalized medicine. Moreover, public and private investments are accelerating the development of these groundbreaking therapies. However, challenges persist, such as high production costs, scalability issues, stringent regulatory environments, and complex manufacturing processes that may hinder market expansion. Opportunities lie in innovating cost-effective manufacturing techniques, enhancing delivery mechanisms, and developing partnerships that facilitate technology sharing to overcome current limitations. CDMOs can capitalize on the burgeoning demand by investing in advanced technology platforms that enhance scalability, regulatory compliance, and speed to market, such as integrated digital solutions and automation. Critical areas of innovation include improving delivery systems, such as lipid nanoparticles, and evolving stable formulation technologies that ensure the safe delivery of nucleic acid payloads to targeted cells. Adapting to the market's nature requires an agile approach, expanding portfolios to include comprehensive services spanning from development to commercial manufacturing. By understanding these market dynamics and potential opportunities, businesses can better position themselves to advance nucleic acid therapeutics, addressing unmet medical needs and driving robust growth within this innovative sector.

KEY MARKET STATISTICS
Base Year [2023] USD 9.69 billion
Estimated Year [2024] USD 10.58 billion
Forecast Year [2030] USD 18.47 billion
CAGR (%) 9.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of genetic disorders worldwide
    • Increasing funding and investments support nucleic acid research
  • Market Restraints
    • High production costs of nucleic acid therapies
  • Market Opportunities
    • Rising regulatory approvals for nucleic acid therapies
    • High potential with the expansion of personalized medicine
  • Market Challenges
    • Limited scalability of nucleic acid therapies

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid Therapeutics CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid Therapeutics CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid Therapeutics CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid Therapeutics CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid Therapeutics CDMO Market

A detailed market share analysis in the Nucleic Acid Therapeutics CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid Therapeutics CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid Therapeutics CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid Therapeutics CDMO Market

A strategic analysis of the Nucleic Acid Therapeutics CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Rentschler Biopharma SE, Sanofi SA, The Scripps Research Institute, Univercells Group, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid Therapeutics CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across DNA Therapeutics and RNA Therapeutics.
  • Based on Service, market is studied across Analytical and Quality Control Services, Manufacturing Services, and Process Development and Optimization.
  • Based on Application, market is studied across Genetic Disorders, Infectious Diseases, and Oncology.
  • Based on End-user, market is studied across Biotech Companies, Government & Academic Research Institutes, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of genetic disorders worldwide
      • 5.1.1.2. Increasing funding and investments support nucleic acid research
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs of nucleic acid therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising regulatory approvals for nucleic acid therapies
      • 5.1.3.2. High potential with the expansion of personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited scalability of nucleic acid therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing advancements in mRNA therapeutics with rising prevalence of infectious diseases
    • 5.2.2. Application: Rising incidence of cancer push the need for innovative and effective cancer treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Type

  • 6.1. Introduction
  • 6.2. DNA Therapeutics
  • 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service

  • 7.1. Introduction
  • 7.2. Analytical and Quality Control Services
  • 7.3. Manufacturing Services
  • 7.4. Process Development and Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Application

  • 8.1. Introduction
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
  • 8.4. Oncology

9. Nucleic Acid Therapeutics CDMO Market, by End-user

  • 9.1. Introduction
  • 9.2. Biotech Companies
  • 9.3. Government & Academic Research Institutes
  • 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
    • 13.3.2. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AGC Biologics Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Ajinomoto Bio-Pharma Services
  • 4. Almac Group Ltd.
  • 5. Biomay AG
  • 6. BioSpring GmbH
  • 7. Catalent, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. CordenPharma International GmbH
  • 10. Creative Biogene
  • 11. Danaher Corporation
  • 12. Eurofins Scientific SE
  • 13. Evonik Industries AG
  • 14. GenScript Biotech Corporation
  • 15. Lonza Group Ltd.
  • 16. Polypeptide Group AG
  • 17. Rentschler Biopharma SE
  • 18. Sanofi SA
  • 19. The Scripps Research Institute
  • 20. Univercells Group
  • 21. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT AND OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GOVERNMENT & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023